Abecma wins CHMP’s thumbs up for use in earlier treatment lines
Bristol Myers Squibb has received a positive opinion from an arm of the European Medicines Agency (EMA) on the use of its CAR T-cell…
Margarida Maia, PhD, science writer — 
Articles by Margarida Maia
AstraZeneca to add CAR T-cell therapy to pipeline with Gracell buy
AstraZeneca is set to buy Gracell Biotechnologies in a deal worth up to $1.2 billion that would add GC012F — an experimental dual-targeting…
Elrexfio approved for hard-to-treat multiple myeloma patients in Europe
The European Commission has granted conditional marketing authorization to Elrexfio (elranatamab) to treat adults with multiple myeloma who received at least prior…
New cases of myeloma rose in US, mostly in young Hispanic women
A study has observed a rise in the number of new cases of myeloma in both men and women in the U.S. since the…
1st patient dosed in Phase 1 trial of triple-target treatment ISB 2001
The first multiple myeloma patient has been dosed in a Phase 1 clinical trial evaluating the safety and efficacy of ISB 2001, Ichnos…
Foundation awards $21M in grants for multicenter myeloma research
Three research projects have been awarded $7 million each from the Multiple Myeloma Research Foundation (MMRF) to develop more effective treatment options for newly…
Aphexda approved in US to improve autologous stem cell transplants
The U.S. has approved BioLineRx’s Aphexda (motixafortide) in combination with filgrastim (G-CSF) to improve the process of autologous hematopoietic stem cell transplant (AHSCT)…
Some myeloma cells may mutate to resist T-cell therapies: Study
Some multiple myeloma cells acquire mutations that allow them to act in disguise and to escape the effects of T-cell therapies, according to a…
Positive early results seen for CAR T-cell therapy for myeloma in trial
Most patients with hard-to-treat multiple myeloma given NXC-201 — Nexcella’s experimental point-of-care CAR T-cell therapy — as part of a clinical trial in…
SP-3164 ‘Molecular Glue’ Stops Growth In Lab-grown Cells, Mice
SP-3164, an investigational small molecule protein degrader, showed potential for improved anti-multiple myeloma activity over similar approved compounds. That’s according to preclinical data from…